[O-34] Oral Session 34
Clinical trial and Regenerative medicine 2 E

[O-34-2] Clinical benefits of eculizumab monotherapy in NMOSD: findings from the phase 3 PREVENT study

^○Larisa Miller¹, Kazuo Fujihara^2,3, Sean J. Pittock⁴, Achim Berthele⁵, Ho Jin Kim⁶, Michael Levy^7,8, Ichiro Nakashima^3,9, Celia Oreja-guevara¹⁰, Jacqueline Palace¹¹, Murat Terzi¹², Natalia Totolyan¹³, Shanthi Viswanathan¹⁴, Kai-chen Wang^15,16, Amy Pace¹, Marcus Yountz¹, Guido Sabatella¹, Róisín Armstrong¹, Dean M. Wingerchuk⁴ (1.Alexion Pharmaceuticals, USA, 2.Fukushima Medical University, 3.Tohoku University, 4.Mayo Clinic, 5.Technical University of Munich, 6.Research Institute and Hospital, Goyang, 7.Johns Hopkins University, 8.Massachusetts General Hospital, 9.Tohoku Medical and Pharmaceutical University, 10.Hospital Universitario Clínico San Carlos, 11.John Radcliffe Hospital, 12.Ondokuz Mayis University, 13.First Pavlov State Medical University of St Petersburg, 14.Kuala Lumpur Hospital, 15.Cheng-Hsin General Hospital, 16.National Yang Ming University)